Ftse Mib
34.553,95
-0,14%
DAX
18.712,12
-0,08%
S&P 500
5.321,14
-0,01%
NASDAQ
16.816,72
-0,09%
Bitcoin
69.477,94
-0,93%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PTC Therapeutics Inc (PTCT) PTC Therapeutics Inc (PTCT) Notizie

PTCT

PTC Therapeutics (PTCT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PTCT
DataOraFonteTitoloSimboloCompagnia
20/05/202418:20PR Newswire (US)PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluationNASDAQ:PTCTPTC Therapeutics Inc
20/05/202413:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTCTPTC Therapeutics Inc
14/05/202413:30PR Newswire (US)PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™NASDAQ:PTCTPTC Therapeutics Inc
10/05/202423:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTCTPTC Therapeutics Inc
07/05/202421:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTCTPTC Therapeutics Inc
02/05/202414:00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:PTCTPTC Therapeutics Inc
25/04/202422:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
23/04/202422:30PR Newswire (US)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PTCTPTC Therapeutics Inc
11/04/202414:00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
28/03/202413:30PR Newswire (US)PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMANASDAQ:PTCTPTC Therapeutics Inc
19/03/202412:30PR Newswire (US)PTC Therapeutics Provides Key Regulatory UpdatesNASDAQ:PTCTPTC Therapeutics Inc
29/02/202422:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
15/02/202414:00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202421:50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202413:13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTCTPTC Therapeutics Inc
25/01/202422:05PR Newswire (US)CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination ProcedureNASDAQ:PTCTPTC Therapeutics Inc
08/01/202415:26PR Newswire (US)PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
03/01/202414:00PR Newswire (US)PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
05/12/202323:24Dow Jones NewsPTC Therapeutics Gives Updates on Translarna Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
05/12/202322:15PR Newswire (US)PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
07/11/202322:16Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:PTCTPTC Therapeutics Inc
26/10/202322:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTCTPTC Therapeutics Inc
26/10/202322:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
19/10/202314:00PR Newswire (US)PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 BillionNASDAQ:PTCTPTC Therapeutics Inc
16/10/202322:30PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results NASDAQ:PTCTPTC Therapeutics Inc
29/09/202313:29IH Market NewsFriday’s Wall Street Highlights: New Integrated, Nike, Tesla, Alphabet, and moreNASDAQ:PTCTPTC Therapeutics Inc
29/09/202302:12Dow Jones NewsStocks to Watch: Nike, Novo Integrated, PTC TherapeuticsNASDAQ:PTCTPTC Therapeutics Inc
28/09/202322:30PR Newswire (US)PTC Announces Further Strategic Prioritization and Associated Reduction in WorkforceNASDAQ:PTCTPTC Therapeutics Inc
15/09/202312:00PR Newswire (US)CHMP Delivers Opinion on Translarna™ for Conversion to Full AuthorizationNASDAQ:PTCTPTC Therapeutics Inc
07/09/202314:00PR Newswire (US)PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient CommunityNASDAQ:PTCTPTC Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PTCT

La tua Cronologia

FX
NZDJPY
NZD vs Yen
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network